Ann: Update on US FDA De Novo Classification Request, page-78

Well in heinsight the hedging Credit Raise was a good decision. Raising cash at these levels would have proven the company is dead. While absolutely guttered and cannot understand the “risks” (what risks? It assists in diagnosis just like a dr with a stethoscope) the Tech works with current TGA and CE approvals. It will be a very slow grind up now as their is no FOMO buying potential and price rise will be solely on management and their ability to close deals. The company will be valued solely on income and deals. Let’s hope they can start making money before their cash runs out then we are really stuffed. I’m still optimistic overall but massively disappointed, especially as I recently dusted off the shares from the bottom drawer. Might be agle
to get them back out in 12 months... maybe